ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > ALK-1

ALK-1

概要

Name:Activin receptor-like kinase 1
Target Synonym:EC:2.7.11.30,ACVRLK1,Activin A Receptor Type II-Like 1,Activin A Receptor, Type II-Like Kinase 1,EC 2.7.11,ALK-1,Serine/threonine-protein kinase receptor R3,TGF-B superfamily receptor type I,Activin receptor-like kinase 1,SKR3,ALK1,ACVRL1,Activin A Receptor Like Type 1,Activin A Receptor Type IL,TSR-I,EC 2.7.11.30,HHT2,ORW2,HHT
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
AL1-H5228 Human Human ALK-1 / ACVRL1 Protein, His Tag
AL1-H5228-structure
AL1-H5228-sds
ACRO Quality

Synonym Name

ACVRL1,ACVRLK1,ALK-1,HHT,HHT2,ORW2,SKR3,TSR-I

Background

Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Ascrinvacumab PF-3446962; GT-90001; PF-3-446-962; GT-90001C; ALK-1; GT90001C; PF-03446962 Phase 2 Clinical Pfizer Inc Solid tumours; Liver Neoplasms; Neoplasms; Mesothelioma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Macular Degeneration Details
Ascrinvacumab PF-3446962; GT-90001; PF-3-446-962; GT-90001C; ALK-1; GT90001C; PF-03446962 Phase 2 Clinical Pfizer Inc Solid tumours; Liver Neoplasms; Neoplasms; Mesothelioma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Macular Degeneration Details

This web search service is supported by Google Inc.

totopphone